NKTR · Bull vs Bear

The case for and the case against Nektar Therapeutics, each point drawn from public SEC filings — who’s buying, the red flags, and the health score. No opinion, no price call. Read both sides, then pick yours.

the bull case // 0

No recent buying across insiders, Congress, or 13F filers, and no standout strength in the filing-based scores. A quiet bull case — not the same as a bear case.

the bear case // 7

Bankruptcy-risk zone

Altman Z-Score is in the distress zone (-11.50).

SEC filing ↗

Short cash runway

Burning cash with roughly 2 months of runway — a dilutive raise looks likely.

SEC filing ↗

Active dilution shelf

An effective S-3 shelf with 6 prospectus filing(s) in 12 months — shares may be getting sold into the market.

SEC filing ↗

Weak fundamentals

Piotroski F-Score of 1/9 — most quality checks are failing.

SEC filing ↗

One-sided insider selling

7 insider sales and no open-market buys in the recent window.

SEC filing ↗

Insiders are selling

7 insider sales recently with no offsetting open-market buys.

SEC Form 4 →

Weak cash position

~2 months of cash left

SEC XBRL

where do you land on NKTR?

Bull Bear

Saved on this device. Your call, from the evidence above — not a recommendation.

Educational only — not financial adviceand never a recommendation to buy or sell. Both sides are built from public SEC filings (Form 4, STOCK Act, 13F, XBRL financials), which lag 40–90 days; absence of a red flag is not a clean bill of health.